Aethlon Medical Publishes Data on Hemopurifier's Removal of Platelet-Derived Extracellular Vesicles

Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications

Aethlon Medical, Inc., a company dedicated to developing medical products for cancer and serious infectious diseases, has announced promising results from a pre-clinical study involving its Hemopurifier®. This innovative blood filtration device is designed to extract harmful extracellular vesicles (EVs) and dangerous viruses from blood and other bodily fluids, showing potential applications not only in treating cancer and infectious diseases but also in organ transplantation and other major medical needs.

Extracellular vesicles derived from platelets (PD-EVs) are the most common EV type in the human body. These vesicles, released by platelets in response to various stimuli, are known to contribute to blood vessel damage, immune cell activation, and the spread of cancer cells. Excessive levels of PD-EVs have been linked to a wide range of illnesses, including cancer, lupus, multiple sclerosis, Alzheimer's, sepsis, and both acute and long COVID.

An independent research group previously discovered that in Alzheimer's patients, PD-EVs bind to Galanthus nivalis agglutinin (GNA), a plant lectin. Based on this, Aethlon Medical hypothesized that their Hemopurifier, which features a unique GNA affinity resin, could effectively remove PD-EVs from plasma. To test this, the company conducted an experiment using 200 milliliters of donated healthy human plasma, simulating a clinical session with the Hemopurifier. The study revealed a significant 98.5% reduction of PD-EVs after a period equivalent to a four-hour treatment.

Dr. Steven P. LaRosa, Aethlon Medical's Chief Medical Officer and senior paper author, expressed enthusiasm over the study's findings, highlighting its importance for their ongoing oncology clinical trial in Australia. The study aims to further investigate the removal of PD-EVs in trial participants, as these vesicles play a role in cancer progression.

Aethlon's CEO, James Frakes, pointed out the broad potential applications of the Hemopurifier, suggesting that its ability to remove PD-EVs could serve as a "pipeline within a device" for multiple therapeutic strategies. The company plans to submit the study's findings to a peer-reviewed medical journal and continue exploring the removal of PD-EVs and their cargo in plasma samples from other relevant diseases.

Aethlon Medical is advancing the Hemopurifier, a cutting-edge immunotherapeutic device aimed at fighting cancer and severe viral infections, as well as aiding in organ transplantation. The device has shown promising results in human trials for removing life-threatening viruses and in pre-clinical studies for eliminating harmful EVs from biological fluids using its proprietary lectin-based technology. The Hemopurifier holds a Breakthrough Device designation from the U.S. FDA for treating advanced or metastatic cancer patients who are unresponsive to standard treatments and suffer from cancer types where EVs contribute to disease progression. It also has FDA designations for addressing life-threatening viruses lacking approved therapies.

The company continues its research and development efforts, with a focus on expanding the Hemopurifier's applications across various medical fields, potentially revolutionizing treatments for several challenging diseases.